PharmaCyte Biotech, Inc. Overview
Pro stress-test →PharmaCyte Biotech is a clinical-stage biotech focusing on developing cellular therapies for difficult-to-treat diseases like pancreatic cancer and diabetes. The company utilizes a proprietary live-cell encapsulation technology called Cell-in-a-Box®, which serves as a platform for multiple therapeutic applications.
Strategic Profile
Pro stress-test →The pipeline spans pancreatic cancer development (CypCaps), diabetes engineering (insulin-producing stem cells), and cannabinoid therapies for brain cancer. However, as of December 1, 2025, the company received notice from NASDAQ that it failed to maintain the minimum $1.00 bid price requirement for continued listing, and CEO Kenneth Waggoner stepped down with the board authorizing a business review committee to evaluate strategic opportunities.
Competitive Landscape
Pro stress-test →PharmaCyte operates in cellular therapy for oncology and diabetes treatment, competing with established biotech firms developing CAR-T, stem cell, and encapsulation-based therapies. Competitors include Juno Therapeutics, Bluebird Bio, and other cellular immunotherapy developers. The company's Cell-in-a-Box platform differentiates via immune-protected cell encapsulation, but clinical progress and capital position lag larger competitors.
Industry Context
PharmaCyte Biotech, Inc. operates in Cellular immunotherapy for oncology.
Key facts
Founded: 1996 · Headquarters: Las Vegas, US · Employees: N/A · Revenue: N/A · Market cap: $7.8M